Skip to content

Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope

Surfactant Administration Via Thin Catheter Using a Specially Adapted Video Laryngoscope - a Prospective Study Assessing the Feasibility of the VISUAL (Video Surfactant Administration Laryngoscopy) Method

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03846960
Acronym
VISUAL
Enrollment
20
Registered
2019-02-20
Start date
2019-11-01
Completion date
2021-12-31
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Keywords

video laryngoscope, minimally invasive surfactant administration

Brief summary

In this study the investigators intend to assess the feasibility of surfactant administration via a thin catheter using a specially adapted video laryngoscope, with a groove designed to allow insertion of an endovascular catheter without the use of other instruments in the oral cavity (forceps ect.). The laryngoscope is of Peak Medic Ltd, Netania, Israel.

Detailed description

A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. Once neonates present respiratory distress, the adapted scope will be used - clinical and outcome measures will be collected to asses the safety and efficacy of the use

Interventions

DEVICEusing specially adapted VNscope

surfactant administration via thin catheter using a specially adapted VNscope

surfactant administration via thin catheter using a specially adapted VNscope

Sponsors

Carmel Medical Center
CollaboratorOTHER
HaEmek Medical Center, Israel
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Intervention model description

intervention of a device product being evaluated in a small clinical trial to determine the feasibility of the product

Eligibility

Sex/Gender
ALL
Age
30 Weeks to 36 Weeks
Healthy volunteers
No

Inclusion criteria

1. \- Premature infants with gestational age 30-36 weeks. 2. \- Diagnosis of respiratory distress syndrome 3. \- Treatment with antenatal steroids. 4. \- Spontaneously breathing with non-invasive positive pressure ventilation. 5. \- maximal age 3 days.

Exclusion criteria

1. \- Apgar score at 5 min \< 5 2. \- Need for chest compressions or medication upon delivery. 3. \- Evident major congenital malformation, metabolic or genetic disorders. 4. \- Clinical evidence of sepsis.

Design outcomes

Primary

MeasureTime frameDescription
Number of attempts until surfactant is administratedmaximal age 3 days.Number of intubation attempts- higher values represent a worse outcome
Assessment of the infants' stability during the procedure - saturation, bradycardia, tachycardia.maximal age 3 days.Monitoring the baby during the procedure and assessment of the infants' stability: hypoxia (Oxygen saturation less than 60% for more than 5 sec), bradycardia (HR less than 60 for more than 5 sec), tachycardia (HR more than 220 for more than 5 sec) bradycardia below 100 bpm and tachycardia above 220 bpm indicate worse outcome
Duration of the entire procedure, form laryngoscope insertion to surfactants administration and Laryngoscope blade out of the mouth.maximal age 3 days.Time measurement of the procedure, sorter time indicate a better outcome

Secondary

MeasureTime frameDescription
Unexpected pitfalls reportsmaximal age 3 days.Physician assessment to evaluate eny pitfalls during the procedure
Need of invasive mechanical ventilation in the next 24 hours.maximal age 3 days.Failure of non-invasive approach and conversion to invasive ventilation to evaluate the efficiency of the procedure
Safety assessment of the procedure (Physician questionnaire)maximal age 3 days.Physician questionnaire- Do you feel VISUAL method is safe for the premature baby? a)Yes b)Maybe c)No
complications reports - one lung surfactant administration, pneumothorax, NEC, IVH, Pulmonary Hemorrhagemaximal age 3 days.Documentation of the complication related to the procedure according to the clinical signs and chest x-ray after the procedure
Subjective procedure scale of assessment.maximal age 3 days.Physician subjective assessment to evaluate the feasibility of the procedure- IRB- approved survey aims to assess user experiences with Video Surfactant Administration Laryngoscopy method in NICU. The survey contains five levels- a) Very satisfied b) Somewhat satisfied c) Neither satisfied nor dissatisfied d) Somewhat dissatisfied e) Very dissatisfied

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026